REG - BioPharma Credit PLC - Notice of AGM

Biopharma CreditAnnouncement

18/04/2024 18:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240418:nRSR2304La&default-theme=true

RNS Number : 2304L  BioPharma Credit PLC  18 April 2024

18 April 2024

BioPharma Credit plc

(the "Company")

NOTICE OF ANNUAL GENERAL MEETING

 

Following the publication on 27 March 2024 of its Annual Financial Report for
the year ended 31 December 2023, the Company announces that it will hold its
Annual General Meeting ("AGM") at 1.00 p.m. on 12 June 2024 at the offices of
Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG.

 

A copy of the Notice of the AGM is available to view on the Company's website
at http://www.bpcruk.com. It has also been submitted to the National Storage
Mechanism and is available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) . Copies of the
Notice of the AGM have been posted or made available to the Company's
Shareholders.

 

Enquiries:

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0) 333 300 1950

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

biopharmacredit@buchanan.uk.com (mailto:biopharmacredit@buchanan.uk.com)

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASFIFMAELSEFL